Business Context and Reporting Period
This Form 8-K Current Report is filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) for the reporting period ending April 7, 2015. The filing details the entry into material definitive agreements involving the sale of equity securities and the creation of a new series of preferred stock.
Key Financial Metrics and Transaction Details
The Company completed two private placements of Series A Preferred Stock and warrants:
- April 1, 2015 Transaction: Sold 110,000 shares of Series A Preferred Stock and warrants to purchase 22,000 common shares to three investors for aggregate proceeds of $275,000 ($2.50 per share).
- April 7, 2015 Transaction: Sold 140,000 shares of Series A Preferred Stock and warrants to purchase 28,000 common shares to two investors for aggregate proceeds of $350,000 ($2.50 per share).
- Total Proceeds: $625,000 from the issuance of 250,000 shares of Series A Preferred Stock.
- Warrant Terms: Exercise price of $5.00 per share with a five-year term.
The filing does not provide data on revenue, operating profit, cash flow, margins, or existing debt levels.
Material Changes and Corporate Actions
On April 1, 2015, the Company filed a Certificate of Designation with the Nevada Secretary of State to create Series A Preferred Stock, authorizing 1,000,000 shares. Key terms include:
- Conversion Price: The lower of the price per share in an Acquisition or Next Equity Financing (if closed within six months) or $2.50.
- Automatic Conversion: Occurs immediately prior to an Acquisition or Next Equity Financing (if within six months) or on the six-month anniversary of the closing date.
- Dividends: Holders are not entitled to receive dividends.
- Correction: On April 7, 2015, a Certificate of Correction was filed to fix a date error in the original Certificate of Designation.
Guidance, Risks, and Unusual Items
The securities were issued pursuant to exemptions under Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D. Investors represented they are accredited investors acquiring securities for investment purposes only. The agreements include a provision allowing investors to request registration of the underlying common stock if the Company files a registration statement with the SEC. No forward-looking guidance or management commentary regarding future financial performance is included in this filing.
Investor Verification Checklist
- Verify the total capital raised ($625,000) against the Company's current cash position and burn rate.
- Review the full text of the Certificate of Designation (Exhibit 3.1) to understand specific anti-dilution or liquidation preferences not detailed in the summary.
- Confirm the timeline for the "Next Equity Financing" or "Acquisition" to determine the automatic conversion trigger date (six months from closing).
- Assess the potential dilution impact of the 50,000 warrants issued at a $5.00 exercise price.